Recent Company News

• 12:07 AM ET May 16, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 05:30 PM ET May 20, 2026
  

  Transcript Intelligence: Belite Bio Q1 Earnings Guidance

• 05:30 PM ET May 20, 2026
  

  Transcript Intelligence: Belite Bio Q1 Earnings Themes

• 05:30 PM ET May 20, 2026
  

  Transcript Intelligence: Belite Bio Q1 Earnings Q&A

• 06:01 AM ET May 20, 2026
  

  Belite Bio reports Q1 EPS ($0.45) vs FactSet ($0.63) [8 est, ($0.96)-(0.47)] ($139.70, 0.00)

• 05:14 PM ET May 18, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:01 PM ET May 18, 2026
  

  Belite Bio receives Orphan Drug status for Tinlarebant in Stargardt Disease in Switzerland ($142.90, 0.00)

• 03:41 PM ET May 15, 2026
  

  Duquesne discloses changes in holdings in 13F filing